PDF Version for Printing
The articles referenced in this Highlights section will be available online in HTML and PDF formats to all interested users at no charge until the next issue of Cancer Research is published. Click on the article title to view the complete article.
View the Table of Contents for the August 1 issue of Cancer Research.
Page 6038
Page 6232
Page 6241
Page 6341
Extending their recent observation that bone marrow–derived dendritic cells (DCs) from aged mice are less effective than those from their younger counterparts in inducing the regression of B16-ovalbumin (OVA) melanomas, Grolleau-Julius and colleagues examined the effect of aging on DC tumor antigen presentation and migration and on their ability to stimulate T cells. Experiments in mice showed defective trafficking of aged DCs to draining lymph nodes, impaired activation of OVA-specific CD8+ T cells, and decreased influx of intratumor CD8+ T cells. Although defective migration could be restored by increasing the number of old DCs injected, the aging defect in DC tumor surveillance and OVA-specific CD8+ T-cell induction remained, suggesting that defective T-cell stimulation contributes to the observed impaired DC tumor immunotherapeutic response in aging.
Klechevsky et al. Page 6360 Melanoma-associated peptides presented as epitopes on MHC class I molecules are attractive targets for immunotoxin-based therapy. By screening a human phage display library, Klechevsky and colleagues isolated two recombinant Fab antibodies which recognize the melanoma-associated antigens MART-1 and gp100 HLA-A201 complexes. The authors then constructed fusion proteins composed of a truncated form of Pseudomonas exotoxin and each of the Fab antibodies. These immunotoxins bound and killed HLA-A201 melanoma Mart-1+ and gp100+ cell lines. In severe combined immunodeficient mice, MART-1 and gp100 immunotoxins significantly inhibited human melanoma growth. These results show that MHC class I/peptide complexes can serve as specific targets for passive immunotherapy for cancer.
Page 6360